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ABSTRACT 
__________________________________________________________________________________________ 
 
Purpose: To measure the CCR5
+
 and CXCR4
+
 
expression on blood lymphocytes, its changes in 
AIDS development, and correlation of CCR5
+
 and 
CXCR4
+
 expression with a number of T-cells, T-
helpers, cytotoxic T-cells, activated T-cells (CD3
+
 
HLA-DR
+
), T-regs cells, natural killer (NK)-cells, 
B cells, in order to determine the type of immune 
response activation in HIV/HCV coinfected 
patients.  
Materials and methods: The patients were divided 
into four groups. The 1
st
 group included 51 patients 
with HIV/HCV coinfection; the 2
nd
 group consisted 
of 23 patients with HIV-infection; the 3
rd
 group was 
composed of 10 patients with HCV-infection. 
Control group consisted of 16 healthy individuals. 
In the current investigation, the monoclonal 
antibodies were used. The cells were analyzed 
using flow cytometer.  
Results: In patients with HIV/HCV coinfection 
СXCR4 expression on blood lymphocytes was 
reduced in comparison with control. СCR5 
expression on blood lymphocytes, HLA-DR  
 
expression on CD3+lymphocytes and cytotoxic T- 
cells, numbers of CD8 T-lymphocytes were 
increased and in the same time the number of 
CD4+CD25+ was reduced in HIV/HCV coinfected 
patients in comparison with the HCV-infected 
patients and control group. 
Conclusions: In chronic HIV/HCV coinfected 
patients СCR5+ expression on blood lymphocytes 
was increased and СCR5+ expression on CD4+ T-
lymphocytes was decreased in comparison with 
healthy individuals and HCV-infected patients. 
With the development of AIDS, CXCR4
+
 and 
CCR5
+
 expressions on CD4
+
T-lymphocytes, 
CXCR4
+
 expressions on blood lymphocytes were 
decreased and CCR5
+
 expression on blood lympho-
cytes was increased. Increased СCR5+ expression 
on blood lymphocytes in HIV/HCV coinfected 
patients was associated with Th1 type immune 
response activation.  
Key words: HIV, HCV, coinfection, immune 
response, chemokine receptors, CCR5, CXCR4. 
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INTRODUCTION 
Hepatitis C virus (HCV)-infection is 
common in human immune deficiency virus (HIV)-
infected individuals because of a similar way of 
transmission. According to the investigation 
performed in 2009 about 50% of total population of 
HIV-infected patients in different regions of 
Belarus was coinfected with HCV [0].  
Chemokine receptors СХСR4 (CD184) and 
CCR5 (CD195) are predominant coreceptors for 
HIV-1 entry into human’s cells. Depending on the 
character of the used coreceptors three variants of 
HIV are distinguished: CCR5/M (R5)-tropic virus, 
CXCR4/T(X4)-tropic virus, R5/X4 dual-tropic 
virus. R5-tropic virus uses CD4 and CCR5 for 
HIV-1 entry into the cell, while X4-tropic HIV uses 
CD4 and CХCR4. Individuals homozygous for the 
CCR5/Δ32 alleles are not susceptible for HIV-
infection because they are not able to express CCR5 
on cell-surface [1, 2].  
 It was established that GB virus C 
coinfection in advanced HIV -1 disease was 
associated with low CCR5 and CXCR4 surface 
expression on CD4
+
 T-cells. It can serve as a 
molecular mechanism for the clinical benefit of GB 
virus C/HIV coinfection in AIDS [3]. Immature 
dendritic cells, on monocytes/macrophages, on 
memory CD4
+
T-cells, on Th1 cells, on CD8
+
T-
cells. On CD4
+
T-cells 4000 to 24 000 CCR5 
molecules may be numerated per cell. Density of 
CCR5 on surface of CD4
+
 T-cell is a surface over 
time in individual but the percentage of CD4
+
 T-
cells expressed CCR5 may drive according to 
circumstances. CCR5
+
 expression on the surface of 
CD4
+
 T-cell increases in HIV infection and stays 
stable for a long time in a given patient [2, 4].  
CХCR4 receptors can be found at 41.6 ± 
16.1% of Т-lymphocytes (CD3+), at 53.5 ± 18.4% 
of В-lymphocytes (CD20+), 20.4 ± 9.4% of 
monocytes (CD14
+
) and are almost absent at natural 
killer (NK) cells (0.2 ± 0.3), neutrophils and 
eosinophils. Expression of CХCR4+ at CD4+ и 
CD8
+
 Т-lymphocytes is approximately the same [5, 
6]. Natural ligands for CCR5 are CCL3 (MIP-1a), 
CCL4, (MIP-1b), CCL5 (RANTES) [1, 2, 7]. 
Chemokine SDF-1 (stromal cell-derived factor-1) is 
a natural ligand for CХCR4; it blocks X4-tropic 
viral cell entry in vitro [8].  
CCR5 is not only a chemokine receptor; it is 
also a coactivation receptor [2, 5]. CCR5 function is 
demonstrated in cellular immune response. CCR5 
are expressed on Th1 cells, producing IL-2 and 
IFN-γ. IL-2 and IFN-γ up-regulate CCR5 expre-
ssion, whereas the type 2 cytokine IL-10 and IL-4 
down-regulates it. CCL3, CCL4 and CCL5-
produced by Th1 cells favor differentiation of 
CD4T-cell into Th1-type, activate macrophages in 
synergism with IFN-γ, acting like cytokines of type 
1. Mice with CCR5 deficit expression were 
defected with the type Th1 of IR [2].  
HIV coreceptors CХCR4+ and CCR5+ are 
known to be expressed on mutually opposed 
subsets of freshly isolated peripheral blood 
lymphocytes. CХCR4 are expressed mostly on 
resting, unactivated naive T cells (CD26low 
CD45RA+ CD45RO–). While CCR5+ Т-cells had 
phenotype (CD26high CD45RA– CD45RO+), what 
corresponds to activated memory cells [5, 9, 10]. 
In this study, we measured the CCR5
+
 and 
CXCR4
+
 expression on blood lymphocytes, its 
changes in AIDS development, and correlation of 
CCR5
+
 and CXCR4
+
 expression with the number of 
T-cells, T-helpers, cytotoxic T-cells, activated T-
cells (CD3
+
 HLA-DR
+
), T-regs cells, natural killer 
(NK)-cells [12], B cells, in order to determine the 
type of immune response activation in HIV/HCV 
coinfected patients.  
 
MATERIALS AND METHODS 
 
The patients were divided into four groups. 
The 1
st
 group included 51 patients with HIV/HCV 
coinfection; the 2
nd
 group consisted of 23 patients 
with HIV-infection; the 3
rd
 group was composed of 
10 patients with HCV-infection. Control group 
consisted of 16 healthy individuals (three men and 
13 women negative for the markers of viral 
hepatitis type B and C and HIV-infection, aged 
32.5±15.1 years).  
To determine the clinical stage of HIV-
infection, WHO classification was used (2006). All 
patients were tested for HBV and HCV serological 
markers using ELISA kits.RNA load and HCV 
genotype was studied using “Amplisens” kits 
(Russia). The diagnosis of HIV-infection was 
verified by detection of antibodies to HIV using 
ELISA and immunoblot.  
Plasma viral loads (VL) of RNA HIV were 
detected using Ampisens monitor (Russia). 
Detectable level of RNA was defined as 500 
copies/mL. In the current investigation the 
following monoclonal antibodies were used 
(Becton Dickenson, USA):  
 CD3 (SK7, FITC) / CD16 (B73.1, PE) + 
CD56 (NCAM 16.2, PE) / CD45 (2D1, 
PerCP) / CD19 (SJ25C1, APC)  
 CD4 (SK3, FITC) /CD8 (SK1, PE) /CD3 
(SK7, PerCP)  
 HLA-DR (L243, APC) 
 CD4 (SK3, APC) 
 CD184 (CXCR4) (12G5, PE) 
 CD195 (CCR5) (2D7/CCR5, FITC) 
 CD25 (M-A251, FITC). 
The blood (100 µL) was incubated with 
monoclonal antibodies for 15 min at four °С, and 
then the erythrocytes were lysed by ammonium 
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chloride solution for 15 min at 18–25 °С. The cells 
were suspended in 300 μL of 1% paraformaldehyde 
solution and analyzed using (FACSCalibur) flow 
cytometer (Becton Dickenson, USA). Cell 
acquisition and analysis were performed using 
(CellQuest) version 3.3 and (Weasel) version 2.9 
software (WEHI, Australia).  
Statistical analysis. Data are presented as 
median and ranges (minimum and max). Normality 
was tested by Shapiro-Wilk’s test. The majority of  
obtained data were significantly different from a  
 
 
normal distribution; therefore, nonparametric tests 
were applied. Differences between groups were 
analyzed via Kruskal-Wallis test and two-tailed 
unpaired nonparametric Mann–Whitney’s test. The 
correlation between variables was evaluated using 
Spearman's rank coefficient (r). A value of p ≤ 0.05 
was considered significant. All calculations were 
performed using the Statistica (StatSoft, USA) and 
StatPlus (AnalystSoft, USA) software. 
 
 
 
 
     Figure 1. Immunophenotypic analysis of peripheral blood lymphocytes (control group) 
 
А –FSC/SSC dot plot; region R0 includes 
lymphocytes. B –FL3/FL2 dot plot. C –FL1/FL2 
dot plot. D –FL1/FL4 dot plot. E –FL3/SSC dot 
plot; region R5 was created to select CD3
+
. F – 
fluorescence histograms for FL1, FL2, FL4 
channels; solid line shows expression of molecules  
 
 
 
 
by cells after incubation with appropriate 
antibodies, dotted line represents negative controls. 
 
RESULTS  
 
Clinical characteristics of patients are 
presented in table 1.  
 
Table 1. Characteristic of patients in groups of observation  
 
Parameters group 1 
HIV/HCV n=51 
group 2 
HIV n=23 
group 3 
HCV n=10 
Age, years  34.1±5.9 33.4±6.3 40.3±11.7 
Men, n.(%) 39 (76.5) 11(47.8) 7 (70) 
Women, n. (%) 12 (23.5) 12 (52.2) 3 (30) 
Injection drugs users (IDUs) n (%) 28 (54.9)*** - 1(10) 
HCV genotype 1, n (%) 17 (51.5)**** - 7 (70)** 
HCV genotype not 1, n (%) 16 (48.5) - 3 (30) 
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1 clinical category, n (%) 22 (43.1) 16 (69.6)  
2 clinical category, n (%) 23 (25.1)
 *** 2 (8.7) **  
3 clinical category, n (%) 4 (7.8) 4 (17.4)  
4 clinical category, n (%) 2 (3.9) 1 (4.4)  
AIDS, n (%) 11 (21.6) 6 (26.1)  
Antiretroviral therapy АRТ, n (%) 17 (33.3) 6 (26.1)  
Note: ** - p<0.05 in comparison with the patients from group 1, *** - p<0.05 in comparison with the patients from group 2, 
test χ2. 
 
According to table 1, the age doesn’t 
significantly differ in the studied groups. There are 
more men in groups 1 and 3, while in a group, two 
distributions of patients according to gender were 
approximately equal. Parenteral route of HIV 
infection due to intravenous drug usage was 
revealed in 55% of cases in group 1, 10% - in group 
3 and was absent in group 2. Seventeen patients 
(33.3%) in group 1  
 
and 6 (26.1%) ones in group 2 received highly 
active antiretroviral therapy (HAART). The 
majority of patients in groups 1 and 2 had a clinical 
category 1 (asymptomatic infection). AIDS inci-
dence was similar in groups 1 and 2. 
Immunological parameters investigated in 
patients are presented in table 2.  
 
 
Table 2. Immunological parameters of patients in the studied groups
 
Parameter 
Median (ranges) 
Control group 
n=16 
group 1 
HIV/HCV =51 
 
group 2 
HIV n=23 
 
group 3 
HCV n=10 
 
CD3-CD16+ CD56+ (%) 
15.10 
(6.3-27.0) 
7.92 (0.8-9.0)*.**** 
8.99 
(0.5-40.9)* 
12.83 
(5.6-23.6) 
CD3-CD16+CD56+ (cells/µL) 
328.69 
(125.7-856.0) 
119.54 (13.0-
672.4) *.**** 
144.67 
(8.3-733.6)* 
198.79 
(135.3-693.7) 
CD19+ (%) 
8.20 
(2.5-18.9) 
5.33 
(0.7-15.5)* 
4.89 
(0.6-11.9)* 
7.32 
(3.07-11.7) 
CD19+ (cells/µL) 
182.18 
(36.6-635.2) 
95.73 
(14.5-342.7)* 
97.23 
(9.2-434.8)* 
148.09 
(34.4-377.9) 
CD3+ (%) 
70.92 
(61.8-80.1) 
80.70* 
(59.4-92.9) 
82.37 (47.9-
95.0)*.**** 
77.40 (65.8-
85.6)*** 
CD3+ (cells/µL) 
1679.51 
(875.7-2433.5) 
1507.56 
(227.4-3181.8) 
1508.75 
(510.0-3009.0) 
1694.44 
(828.8-2890.6) 
CD3+CD4+ (%) 
41.54 
(27.2-55.6) 
21.32 
(4.2-43.2)*.**** 
25.39 
(0.92-49.8) *.**** 
37.75 
(28.5-54.1)**.*** 
CD3+CD4+ (cells/µL) 
 
934.38 
(467.3-1876.1) 
394.28 
(13.1-58.8)*.**** 
508.39 
(13.8-1228.2)* 
882.81 
(346.0-1314.6)** 
CD3+CD8+ (%) 
 
24.12  
(14.9-37.2) 
54.60 
(32.0-81.8)*.**** 
48.89 
(15.9-81.3)*.**** 
31.73 
(22.3-46.8)*.**.*** 
CD3+CD8+ (cells/µL) 
551.01 
(304.4-874.5) 
957.74 (196.7-
2299.2)*.**** 
912.64 (254.1-
2145.4)*.**** 
577.80 (341.0-
1689.3)**.*** 
CD4/CD8 
1.69 
(0.7-3.7) 
0.44 
(0.1-1.3)*.**** 
0.49 
(0.0-2.0)*.**** 
1.15 
(0.7-2.3)*.**.*** 
Note: * - p<0.05 if compared with control, ** - p<0.05 in comparison with the patients from group 1, *** - p<0.05 in 
comparison with the patients from group 2, **** - p<0.05 in comparison with the patients from group 3, Mann–Whitney U 
test. 
 
According to table 2, NK-cells (CD3
–
CD16
+
CD56
+
) (percentage and absolute values) 
were significantly reduced in the groups of HIV-
infected patients in comparison with the control 
group. Moreover, in a group one value of NK-cells 
was decreased in comparison with group 3. 
Reduction of B-lymphocytes (percentage and 
absolute values) was marked in groups of HIV- 
infected patients (group 1 and 2) if compared with  
 
the control group. The percentage of CD3
+
-  
lymphocytes was significantly higher in the patients 
of groups 1, 2 and 3 in comparison with the control 
group. However, the absolute number of CD3
+
-cells 
did not differ significantly in the studied groups. 
Significant reduction of CD3+CD4+ percentage 
was detected in groups 1 and 2 in comparison with 
the control group and group 3. Absolute number of 
CD3
+
CD4
+
 cells in groups 1 and 2 was significantly 
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lower as compared to the control group, and in 
group 1, it was lower than in group 3.  
 Table 2 shows that CD3
+
CD8
+ 
indicator 
was significantly higher in relative as well as 
absolute values in HIV-infected patients (groups 1 
and 2) in comparison with control and group 3. The 
reduction of CD4
+
/CD8
+
 (immune-regulatory index 
- IRI) was established in all patient groups in 
comparison with the control group. Though, more 
evident reduction of IRI value was detected in the 
groups 1 and 2 in comparison with the group 3.  
HLA-DR expression on Т-lymphocytes and 
their subpopulations is presented in table 3. 
 
 
Table 3. Parameters of HLA-DR expression on blood lymphocytes and T- lymphocytes in the studied groups  
  
 Parameters 
Median (ranges) 
Control group 
n=16 
group 1 
HIV/HCV  =51 
 
group 2 
HIV n=23 
 
 group 3 
HCV n=10 
 
HLA-DR (%) 
21.20 
(15.6-36.3) 
45.79 
(17.3-71.6)*.**** 
39.14 
(14.7-70.6)*.**** 
17.17 
(11.3-42.5) 
HLA-DR cells/µL 
574.96 (225.9-
1269.2) 
789.61 (140.3-
1669.7)*.**** 
624.12 (215.3 
-2136.6) 
378.99 
(120.5-1534.3) 
CD3+HLA-DR+ (%) 
8.60 
(2.2-18.7) 
30.64  
(10.8-67.6)*.**** 
29.45 
(8.0-60.5)*.**** 
7.66 
 (4.3-22.73) 
CD3+HLA-DR+ cells/µL 
176.81 
(60.9-652.8) 
549.63 (74.3-
1626.5)*.**** 
418.74 (143.0-
1581.4)*.**** 
138.82 
(77.2-796.6) 
CD4+HLA-DR+ (%) 4.95 (2.9-9.9) 4.09 (1.6-10.0) 4.07 (1.2-11.6) 3.72 (2.4-9.1) 
CD4+HLA-DR+ cells/µL 
101.46 
(64.5-345.4) 
66.64 
(10.0-274.5)* 
70.03 
(18.4-153.5)* 
81.83  
(29.0-186.1) 
CD8+HLA-DR+ (%) 
5.43  
(2.3-17.0) 
30.88  
(11.0-60.3)*.**** 
27.93 
(8.5-61.6)*.**** 
6.72  
(3.6-18.4) 
CD8+HLA-DR+ cells/µL 
114.74  
(63.9-577.9) 
506.07 (100.0-
1655.3)*.**** 
454.47 (170.2 -
1568.9)*.**** 
124.0 
(62.8-664.7) 
Note: * - p<0.05 if compared with control, ** - p<0.05 in comparison with the patients from group 1, *** - p<0.05                          
in comparison with the patients from group 2, **** - p<0.05 in comparison with the patients from group 3, Mann–Whitney 
U test. 
 
Table 3 shows the increased expression of 
HLA-DR on blood lymphocytes, CD3
+
 and CD8
+
T-
cells in HIV-infected patients (1 and two groups) in 
comparison with controls as well as with group 3 
(mono-HCV). In the group 1 (HIV/HCV coinfected 
patients) there were no differences in percentage of 
HLA-DR expression on CD4
+
 cells between the 
control group and group 3. In the groups 1 and two 
reduction of the absolute index, CD4
+
HLA-DR
+
 
was detected in comparison with the control group. 
Expression of CD25
+
 on the peripheral blood 
lymphocytes and CD4
+
 T- lymphocytes is presented 
in table 4. 
 
Table 4. Parameters of CD25 expression on blood lymphocytes and CD4 T- lymphocytes in studied groups 
 
 Parameters  
Median (ranges) 
Control 
 group n=16 
group1  
HIV/HCV n=51 
group 2 
HIV n=23 
group 3 
HCV n=10 
CD25+ (%) 5.50 (3.5-8.5) 3.82 (0.5-9.5)* 3.94 (1.4-18.9)* 5.14 (2.8-14.0) 
CD25+ cells/µL 
128.30  
(54.8-243.1) 
64.93 
(7.6-260.5)*.**** 
77.75 
(13.3-283.0)* 
108.82 
(35.3-170.2)** 
CD4+ CD25+ (%) 3.55 (2.2-6.0) 1.80 (0.3-6.7)*. **** 2.29 (0.3-4.4)*.**** 3.89 (1.4-8.1)**.*** 
CD4+ CD25+ cells/µL 
87.79  
(40.9-162.1) 
34.4 
(1.0-224.0)*. **** 
41.75 
 (5.2 -112.0)*.**** 
87.69  
(22.2-126.4)**.*** 
Note: * - p<0.05 if compared with control, ** - p<0.05 in comparison with the patients from group 1, *** - p<0.05 in 
comparison with the patients from group 2, **** - p<0.05 in comparison with the patients from group 3, Mann–Whitney U 
test. 
  
According to table 4, in groups 1 and 2 the 
reduction of percentage and absolute number of 
CD25
+
 expression on blood lymphocytes was 
detected in comparison with the control group. 
Absolute value of this parameter in group 1 was 
also significantly lower than in group 3. The 
reduction of percentage and absolute number of 
CD4
+
CD25
+ 
regulatory cells was observed in 
groups 1 and 2 in comparison with groups 3 and the 
control group. The expression of CXCR4
+
 and 
CCR5
+
 on blood lymphocytes in studied groups is 
presented in table 5.  
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Table 5. Parameters of CXCR4 and CCR5 expression on blood lymphocytes and CD4T- lymphocytes in studied 
groups  
 
Parameters 
Median (ranges) 
Control group 
n=16 
 group 1 
HIV/HCV n=51 
group 2 
HIV n=23 
group 3 
HCV n=10 
СХСR4+ (%) 15.51 (8.9-24.8) 13.0 (3.7-33.0) 18.65(0.04-35.6) 15.60 (9.1-35.5) 
СХСR4+ cells/µL 
 
345.56 
(172.1-812.1) 
226.39 
(28.7-973.9)* 
274.28 
(0.7-863.0) 
268.22 
(113.1-1043.5) 
СD4+CXCR4+ (%) 4.15 (1.1-8.1) 4.22 (0.6-17.9) 6.16 (0-15.3) 6.34 (3.4-18.4) 
СD4+CXCR4+ cells/µL 82.42 (33.0-276.8) 64.55 (4.1-510.0) 93.05 (0-439.9) 92.82 (41.0-540.3) 
CCR5+ (%) 
20.67 (12.3-35.8) 32.74 (5.9-
61.3)*.**** 
27.98 (8.9-49.0)**** 18.69 (9.8-30.1)**** 
CCR5+ cells/µL 
 
434.47 
(225.9-975.1) 
579.47 (132.7-
1555.7)**** 
505.18 (110.2-
1586.9) 
337.04 (175.8-
730.1)** 
СD4+CCR5+ (%) 6.11 (0.1-1.2) 2.78 (0.6-11.7)*.**** 2.8 (0.7-7.2)*.**** 4.97 (3.0-12.6)**.*** 
СD4+CCR5+ cells/µL 
 
119.25 (1.0-41.9) 50.17 (3.1-10.0)**** 51.95 (8.5-29.0)**** 128.91 (36.7-
205.6)**** 
СD4+CXCR4+CCR5+ (%) 0.24 (1.1-8.1) 0.24 (0.0-1.7)**** 0.26 (0-2.1)**** 0.5 (0.1-1.5)**.*** 
СD4+CXCR4+CCR5+ 
cells/µL 
6.66 (33.0-276.8) 3.78 (0.0-22.02)**** 3.39 (0-21.1)**** 9.02 (1.3-43.8)**.*** 
Note: * - p<0.05 if compared with control, ** - p<0.05 in comparison with the patients from group 1, *** - p<0.05 in 
comparison with the patients from group 2, **** - p<0.05 in comparison with the patients from group 3, Mann–Whitney U 
test. 
 
The absolute number of СXCR4+ on blood 
lymphocytes was significantly lower in the 1
st
 
group in comparison with the control group 
(Tab.5). The expression of СXCR4+ on CD4+ T-
lymphocytes did not differ statistically in studied 
groups. The percentage and absolute parameter of 
СCR5+ on blood lymphocytes was significantly 
higher in the 1st group in comparison with the 
control group and group 3. The percentage of 
СCR5+ in group 2 was significantly higher in 
comparison with controls and group 3. The 
percentage  and  absolute   parameters   of   СD4+   
 
ССR5+ in groups 1 and 2 were significantly lower 
in comparison with groups 3 and controls. The 
percentage and absolute parameters of 
СD4+CXCR4+ССR5+ cells in groups 1 and 2 were 
significantly lower in comparison with groups 3 
and did not differ significantly with controls. We 
have compared the expression of ССR5+ and 
СXCR4+ on blood lymphocytes and СD4+ T-
lymphocytes
 
in patents of group 1 (HIV/HCV 
coinfection) according to presence or absence of 
AIDS (Tab.6).  
 
Table 6. Parameters of CXCR4 and CCR5 expression on blood lymphocytes and CD4T- lymphocytes in AIDS 
and non AIDS patients with HIV/HCV  
  
Parameters 
Median (ranges) 
Non AIDS  
n= 40 
AIDS 
 n= 11 P 
СХСR4+ (%) 14.4 (3.7 –30.6) 9.9 (6.0 – 33.0) NS 
СХСR4+ cells/µL 241.0 (56.7 – 715.0) 134.7 (53.9 – 973.9) <0.002 
СD4+CXCR4+ (%) 4.8 (1.0 – 17.9) 1.3 (0.8 – 17.3) <0.004 
СD4+CXCR4+ cells/µL 92.2 (16.6 – 407.3) 18.0 (7.1 –510.0) NS 
CCR5+ (%) 29.3 (5.9 –61.2) 46.5 (35.5 – 61.3) <0.03 
CCR5+ cells/µL 595.5 (132.7 – 1555.7) 512.4 (322.4 –1099.8) <0.002 
СD4+CCR5+ (%) 3.1 (0.6 –11.7) 2.3 (2.0 – 6.8) NS 
СD4+CCR5+ cells/µL 59.6 (13.3 –210.0) 31.4 (22.8 – 62.2) <0.001 
Note: * – NS – not signiﬁcant (Mann-Whitney U Test). 
 
AIDS was established if a number of СD4+ 
T-lymphocytes were less than 200 cells/mkl and/or 
if a patient had the fourth stage of HIV-infection 
according to WHO classification, 2006. Expression 
of СXCR4+ on blood lymphocytes was decreased in 
AIDS group in comparison with non AIDS. On the 
other hand expression of СCR5+ on blood 
lymphocytes was increased in AIDS group in 
comparison with non-AIDS group. A relative 
parameter of СXCR4+ and an absolute parameter of  
 
СCR5+ expressions on CD4+ T-lymphocytes were 
decreased significantly in AIDS group in 
comparison with non AIDS. Besides expression of  
СCR5+ on blood lymphocytes was positively 
correlated with AIDS (R=0.50, p=0.0002) and with  
plasma viral load of HIV (R=0.37; p=0.02) in 
HIV/HCV coinfected patients. 
Relative and absolute parameter of the 
ССR5+ expression on СD4+ T-lymphocytes in 
patients with AIDS was reduced in comparison 
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with the patients without it. There were no 
differences detected in СXCR4+ expression on 
СD4+ T-lymphocytes in the compared groups.  
Correlation of СXCR4+ expression on blood 
lymphocytes with some other parameters were 
established (Tab.7). 
 
Table 7.Correlations of CXCR4 expression on BL with immunological parameters in studied groups 
 
Parameters 
 
Control group 
n=16 
group 1 
HIV/HCV n=51 
group 2 
HIV n=23 
group 3 
HCV n=10 
CD3-CD16+ CD56+ (%) 
 
R=-0.81 p<0.0002 NS NS NS 
CD3-CD16+CD56+ (cells/µL) 
 
R=-0.50 p<0.0002 NS NS R=0.83 p=0.003  
CD19+ (%) R=0.59 p<0.02 R=0.32 p<0.02 NS R=0.66 p<0.05 
CD19+ (cells/µL) NS R=0.48 p<0.0003 NS NS 
CD3+CD4+(%) R=0.69 p<0.003 R=0.38 p<0.005 R=0.53 p<0.01 NS 
CD3+CD4+ (cells/µL) NS R=0.39 p=0.006 R=0.51 p=0.01 NS 
CD3+CD8+ (%) NS R= –0.28 p<0.05 NS NS 
CD3+CD4+/ CD3+CD8+ 
(IRI*) 
NS R=0.35 p<0.01 NS NS 
CD4+CD25+ (cells/µL) NS R=0.45, p<0.03 NS NS 
CD4+СXCR4 (%) R=0.65 p=0.06 R=0.81 p<0.0001 R=0.85 p<0.0001 R=0.82 p=0.004 
CD4+СXCR4 (cells/µL) R=0.59 p=0.02 R=0.78 p<0.0001 R=0.83 p<0.0001 R=0.62 p=0.03 
 Note: NS – not signiﬁcant (Spearman Rank Order Correlations); *IRI - immunoregulatory index 
 
Positive correlation of CXCR4
+
 expression 
on blood lymphocytes with CD4
+СXCR4+ Т-cells 
was detected in all observation groups. 
Positive correlation of СXCR4+ with 
CD4
+
CD25
+
,
 
CD3
+
CD4
+
,
 
CD19
+ 
cells was detected  
 
 
 
as well as inverse correlation of СXCR4+ with 
CD3
+
CD8
+
 count in HIV/HCV coinfected patients.  
Correlation of СCR5+ expression on blood 
lymphocytes with some other parameters is given in 
table 8.  
 
Table 8. Correlations of CCR5 with immunological parameters in studied groups 
 
Parameters Control group 
n=16 
group 1 
HIV/HCV n=51 
group 3 
HIV n=23 
group 3 
HCV n=10 
CD3-CD16+ CD56+ (%) R=0.56 p<0.02  
NS NS NS 
CD19+ (cells/µL) NS R= -0.55 p<0.0001 NS NS 
CD3+CD4+  R= -0.50 p<0.05  NS R= -0.60 p<0.002 NS 
CD3+CD4+ (cells/µL) NS R=-0.62 p<0.0001  R=-0.50 p=0.02 NS 
CD3+CD8+ (%) NS R=0.47 p<0.001 R=0.87 p<0.0001 NS 
CD3+CD4+/CD3+CD8+ (IRI*) NS R= -0.58 p<0.0001  R=-0.73 p<0.0001 NS 
CD4+CD25+ (%) NS R= -0.39 
p=0.005  
NS NS 
CD4+CD25+ (cells/µL) NS R=-0.55 p<0.02  NS NS 
HLA-DR (%) NS 
R=0.62 p<0.0001  R=0.56 p=0.005  NS 
CD3+HLA-DR+ (%) R=0.51 p=0.04  R=0.66 p<0.0001  R=0.74 p<0.0001  R=0.66 p=0.04  
CD3+HLA-DR+ , cells/µL NS NS R=0.51 p<0.01  
CD4+HLA-DR+ (%) NS NS NS R=0.64 p=0.04  
CD4+HLA-DR+, cells/µL NS R=-0.28 p<0.05 NS NS 
CD8+HLA-DR+ (%) NS R=0.66 p<0.0001  R=0.72 p<0.0001  NS 
CD8+HLA-DR+ cells/µL NS NS R=0.45 p<0.03  NS 
CD4+СCR5 (%) R=0.73 P=0.001 NS NS NS 
CD4+СCR5 (cells/µL) NS NS NS R=0.73 p=0.02 
 Note: NS – not signiﬁcant (Spearman Rank Order Correlations); *IRI - immunoregulatory index
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In group 1 positive correlations of СCR5+ 
expression on blood lymphocytes were detected 
with number of T-lymphocytes, cytotoxic T-cells, 
activated T-lymphocytes and cytotoxic T-cells as 
well as inverse correlations were established with 
number of T helper cells, CD4
+
CD25
+
 cells.  
 
DISCUSSION 
 
Studies of CCR5
+
 and CRCX4
+
 expression 
on blood lymphocytes and CD3
+
CD4
+
 lympho-
cytes, as well as some immunity parameters 
enabled to detect some significant differences in the 
studied groups.  
We estimated that in patients with HIV/HCV 
coinfection CCR5
+
 expression on CD4
+
                          
T-lymphocytes was decreased and on the other 
hand CCR5
+
 expression on blood lymphocytes was 
increased. It may be associated with the changes of 
HIV tropism during course of HIV-infection. 
Opposite dynamics of CCR5
+
 and CXCR4
+
 
expressions on blood lymphocytes were marked 
with the development of AIDS: CXCR4
+
 
expression was decreased and CCR5
+
 expression 
was increased. Recently published data by 
Schwarze-Zander et al. demonstrated that favorable 
course of AIDS at coinfection GB-C/HIV was 
associated with down-regulation of СCR5+ and 
СXCR4+ expression on СD4+ T-lymphocytes in 
patients without СCR5/Δ32 mutation [3]. In our 
study the presence of СCR5/Δ32 mutation in the 
patients was not detected. However, we revealed 
the decrease in an absolute parameter of СCR5+ 
expression and a relative parameter of СXCR4+ 
expression on СD4+ T-lymphocytes in patients with 
AIDS in comparison with patients without it among 
HIV/HCV coinfected persons.  
Positive correlation of CXCR4
+
 expression 
on blood lymphocytes with number of 
CD4
+СXCR4+ Т-cells detected in all observation 
groups, it may be explained by predominant 
expression of СXCR4 molecule like HIV-
coreceptor on CD4+T cells [1];  
In contrast to СXCR4+ positive correlations 
between ССR5+ expression on blood lymphocytes  
with СD4+ССR5+ Т-cells were not detected in HIV-
infected patients (groups 1 and 2) due to expression 
of this HIV coreceptor on the blood lymphocytes 
outside T-cells system: macrophages, monocytes, 
NK, especially in HIV-infection [1, 2]. HIV 
coreceptors CCR5
 
and
 СXCR4 function as 
chemokine receptors and their expression on cells is 
associated with certain type of immune response 
[3].  
Our results confirmed that СCR5+ was 
correlated with activation of cellular immune 
response in HIV/HCV coinfected patients as well as 
in the remained studied groups while СXCR4+ 
expression was associated with suppression of 
immune response. Positive correlations of CCR5
+
 
expression on blood lymphocytes were detected with 
expression of activation markers of immune 
response HLA-DR [1, 13] and negative correlations 
with inhibition markers of immune response 
(CD4
+
CD25
+
T-lymphocytes) [14-18], while 
СXCR4+ expression positively correlated with 
CD4
+
CD25
+
 T-lymphocytes. CCR5
+
 expression on 
blood lymphocytes positively correlated with the 
level of CD8
+
T-lymphocytes, and negatively with 
the CD19
+
 B-lymphocytes. While the expression of 
CXCR4
+
 positively correlated with the level of 
CD19
+
 B-lymphocytes, and negatively with the level 
of CD8
+
-lymphocytes in HIV/HCV coinfected 
patients. Direct correlation CCR5
+
 expression with 
the HIV viral load, and reverse correlation with the 
level of CD4
+
-lymphocytes was also found out in 
patients with HIV/HCV coinfection, which was 
associated with increased immunity activation with 
the progression of HIV infection. According to 
received data development of AIDS leads to increase 
of Th1 type immune response activation in 
HIV/HCV coinfected patients.  
The limitation of our study include the 
absence of detection of HIV tropism to CCR5 and 
CXCR4 coreceptors and correlations of HIV tropism 
with immunological and clinical data of HIV-
infected patients involved in the study.  
 
CONCLUSIONS 
 
Based on the obtained results, analysis and  
scientific literature data we can conclude that in 
chronic HIV/HCV coinfected patients СCR5+ 
expression on blood lymphocytes was increased and 
СCR5+ expression on CD4+ T-lymphocytes was 
decreased in comparison with healthy individuals 
and HCV-infected patients. With the development of 
AIDS CXCR4
+
 and CCR5
+
 expressions on CD4
+
T-
lymphocytes, CXCR4
+
 expression on blood 
lymphocytes were decreased and CCR5
+
 expression 
on blood lymphocytes was increased. Increased 
СCR5+ expression on blood lymphocytes in 
HIV/HCV coinfected patients was associated with 
Th1 type immune response activation.  
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